Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New painkiller cebranopadol tested for Post-Surgery relief

NCT ID NCT06423703

First seen Jan 10, 2026 · Last updated May 25, 2026 · Updated 26 times

Summary

This study tested a new pain medicine called cebranopadol in 240 adults who had bunion surgery. The goal was to see if it safely reduces moderate to severe pain better than a placebo or another painkiller. Participants rated their pain and satisfaction, and researchers tracked how many needed extra rescue medication.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE PAIN are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • ALLEVIATE 2 Site 001101

    Salt Lake City, Utah, 84107, United States

  • ALLEVIATE 2 Site 001102

    Atlanta, Georgia, 30331, United States

  • ALLEVIATE 2 Site 001103

    Tampa, Florida, 33613, United States

  • ALLEVIATE 2 Site 001104

    McAllen, Texas, 78501, United States

  • ALLEVIATE 2 Site 001105

    Pasadena, Maryland, 21122, United States

  • ALLEVIATE 2 Site 001106

    Little Rock, Arkansas, 72211, United States

  • ALLEVIATE 2 Site 001107

    Overland Park, Kansas, 66212, United States

  • ALLEVIATE 2 Site 001108

    Sheffield, Alabama, 35660, United States

  • ALLEVIATE 2 Site 001111

    San Antonio, Texas, 78240, United States

  • Alleviate 2 001113

    Houston, Texas, 77043, United States

Conditions

Explore the condition pages connected to this study.